Hemant Phatak

2.1k total citations
87 papers, 1.7k citations indexed

About

Hemant Phatak is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Oncology. According to data from OpenAlex, Hemant Phatak has authored 87 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Cardiology and Cardiovascular Medicine, 21 papers in Internal Medicine and 18 papers in Oncology. Recurrent topics in Hemant Phatak's work include Atrial Fibrillation Management and Outcomes (34 papers), Venous Thromboembolism Diagnosis and Management (21 papers) and Health Systems, Economic Evaluations, Quality of Life (16 papers). Hemant Phatak is often cited by papers focused on Atrial Fibrillation Management and Outcomes (34 papers), Venous Thromboembolism Diagnosis and Management (21 papers) and Health Systems, Economic Evaluations, Quality of Life (16 papers). Hemant Phatak collaborates with scholars based in United States, Germany and United Kingdom. Hemant Phatak's co-authors include Joseph Thomas, Gregory Y.H. Lip, Jack Mardekian, Cristina Masseria, Sarah Batson, Shital Kamble, Xianchen Liu, Murtuza Bharmal, Larry Z. Liu and Alexander T. Cohen and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Hemant Phatak

85 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hemant Phatak United States	22	1.0k	390	277	190	187	87	1.7k
Agustín Urrútia Spain	32	1.7k 1.7×	108 0.3×	135 0.5×	72 0.4×	332 1.8×	71	2.5k
Brahim Bookhart United States	20	668 0.7×	649 1.7×	211 0.8×	28 0.1×	206 1.1×	112	1.4k
Carmen Suárez Spain	22	1.0k 1.0×	709 1.8×	144 0.5×	53 0.3×	465 2.5×	87	1.8k
Sue Hee Sung United States	21	1.1k 1.1×	217 0.6×	137 0.5×	31 0.2×	231 1.2×	65	1.6k
Vincent J. Willey United States	23	372 0.4×	169 0.4×	483 1.7×	80 0.4×	552 3.0×	91	1.8k
Anders Gorst‐Rasmussen Denmark	20	906 0.9×	300 0.8×	75 0.3×	90 0.5×	117 0.6×	56	1.5k
Kueiyu Joshua Lin United States	21	460 0.4×	124 0.3×	130 0.5×	110 0.6×	233 1.2×	82	1.4k
Pierluigi Tricoci United States	27	1.6k 1.6×	276 0.7×	289 1.0×	46 0.2×	907 4.9×	107	2.7k
Giulio Francesco Romiti Italy	25	1.5k 1.5×	274 0.7×	276 1.0×	70 0.4×	185 1.0×	114	2.2k
Alexander C. Fanaroff United States	20	942 0.9×	84 0.2×	228 0.8×	45 0.2×	407 2.2×	104	1.8k

Countries citing papers authored by Hemant Phatak

Since Specialization

Citations

This map shows the geographic impact of Hemant Phatak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hemant Phatak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hemant Phatak more than expected).

Fields of papers citing papers by Hemant Phatak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hemant Phatak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hemant Phatak. The network helps show where Hemant Phatak may publish in the future.

Co-authorship network of co-authors of Hemant Phatak

This figure shows the co-authorship network connecting the top 25 collaborators of Hemant Phatak. A scholar is included among the top collaborators of Hemant Phatak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hemant Phatak. Hemant Phatak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Steuten, Lotte, et al.. (2019). Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA. Applied Health Economics and Health Policy. 17(5). 733–740. 10 indexed citations

Zheng, Ying, Tongtong Yu, Jill Dreyfus, et al.. (2019). PCN171 COST AND HEALTHCARE RESOURCE UTILIZATION (HRU) RESULTING FROM IMMUNE-RELATED ADVERSE EVENTS (IRAES) AMONG PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS (ICIS). Value in Health. 22. S469–S469.

Proskorovsky, Irina, Tereza Lanitis, Matthias Hünger, et al.. (2018). Projecting Overall Survival (OS) With Immuno-Oncology (IO) Treatments: Application of Alternative Approaches in Metastatic Merkel Cell Carcinoma (MMCC). Value in Health. 21. S6–S6. 1 indexed citations

Lip, Gregory Y.H., Xianying Pan, Shital Kamble, et al.. (2018). Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban. PLoS ONE. 13(4). e0195950–e0195950. 44 indexed citations

Lip, Gregory Y.H., Xianying Pan, Shital Kamble, et al.. (2016). Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States. International Journal of Clinical Practice. 70(9). 752–763. 93 indexed citations

Lip, Gregory Y.H., Allison Keshishian, Shital Kamble, et al.. (2016). REAL WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS NEWLY INITIATED ON APIXABAN, WARFARIN, DABIGATRAN OR RIVAROXABAN: A 1:1 PROPENSITY-SCORE MATCHED ANALYSIS. Journal of the American College of Cardiology. 67(13). 882–882. 7 indexed citations

Lip, Gregory Y.H., Tereza Lanitis, Thitima Kongnakorn, et al.. (2015). Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation. Clinical Therapeutics. 37(11). 2476–2488.e27. 6 indexed citations

Phatak, Hemant, et al.. (2015). Simulated Treatment Comparison of Time-To-Event (And Other Non-Linear) Outcomes. Value in Health. 18(7). A719–A719. 4 indexed citations

Kamae, Isao, Yoichiro Hashimoto, Yukihiro Koretsune, et al.. (2015). Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan. Clinical Therapeutics. 37(12). 2837–2851. 22 indexed citations

10.

Cohen, Alexander T., M. Hamilton, S.A. Mitchell, et al.. (2015). Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS ONE. 10(12). e0144856–e0144856. 134 indexed citations

11.

Pan, Xianying, Sumesh Kachroo, Xianchen Liu, Hugh Kawabata, & Hemant Phatak. (2014). REAL WORLD DISCONTINUATION RATES WITH APIXABAN VERSUS WARFARIN, DABIGATRAN, OR RIVAROXABAN AMONG ATRIAL FIBRILLATION PATIENTS NEWLY INITIATED ON ANTICOAGULATION THERAPY: EARLY FINDINGS. Journal of the American College of Cardiology. 63(12). A415–A415. 10 indexed citations

12.

Kachroo, Sumesh, Hemant Phatak, Paul Dorian, et al.. (2014). Validation Of The Apixaban Cost-Effectiveness Model In Patients With Non-Valvular Atrial Fibrillation. Value in Health. 17(3). A113–A113. 1 indexed citations

13.

DeMuro, Carla, et al.. (2014). Literature Review Of Pro Measures Assessing Anticoagulant Therapy. Value in Health. 17(7). A495–A496. 1 indexed citations

14.

Liu, Xianchen, Margot Johnson, Jack Mardekian, et al.. (2014). APIXABAN REDUCES HOSPITALIZATIONS IN PATIENTS WITH VTE: AN ANALYSIS OF THE AMPLIFY TRIAL. Journal of the American College of Cardiology. 63(12). A2045–A2045. 3 indexed citations

15.

Cowper, Patricia A., Wenqin Pan, Kevin J. Anstrom, et al.. (2013). APIXABAN REDUCES HOSPITALIZATION IN PATIENTS WITH ATRIAL FIBRILLATION: AN ANALYSIS OF THE EFFECT OF APIXABAN THERAPY ON RESOURCE USE IN THE APIXABAN FOR REDUCTION IN STROKE AND OTHER THROMBOEMBOLIC EVENTS IN ATRIAL FIBRILLATION TRIAL. Journal of the American College of Cardiology. 61(10). E1576–E1576. 9 indexed citations

16.

Phatak, Hemant, et al.. (2013). Epidemiology and mortality of venous thromboembolism across patient populations: A systematic literature review. Value in Health. 16(3). A272–A272. 6 indexed citations

17.

Phatak, Hemant, et al.. (2013). Quality of Life in Patients with Venous Thromboemoblism: A Systematic Literature Review. Value in Health. 16(7). A533–A533. 2 indexed citations

18.

Phatak, Hemant, et al.. (2008). Lipid Testing among Patients Beginning Statin Therapy in General Practice in the United Kingdom. Value in Health. 11(5). 933–938. 3 indexed citations

19.

Phatak, Hemant & Donald Yin. (2006). Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA_1c:a meta-analysis of published randomized clinical trials. Current Medical Research and Opinion. 22(11). 2267–2278. 19 indexed citations

20.

Phatak, Hemant, et al.. (2005). Retrospective Detection of Potential Medication Errors Involving Drugs with Similar Names. Journal of the American Pharmacists Association. 45(5). 616–624. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact